Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month Low – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s share price reached a new 52-week low during trading on Friday . The company traded as low as $3.06 and last traded at $3.18, with a volume of 225854 shares traded. The stock had previously closed at $3.34.

Analyst Upgrades and Downgrades

IRWD has been the subject of a number of research analyst reports. Wells Fargo & Company lowered their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Craig Hallum lowered their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Finally, StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Stock Down 4.5 %

The stock has a market cap of $510.50 million, a PE ratio of -111.33 and a beta of 0.41. The company has a fifty day moving average price of $4.07 and a 200 day moving average price of $5.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 earnings per share. As a group, research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC boosted its holdings in Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 2,345 shares during the last quarter. KBC Group NV boosted its position in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,198 shares during the period. GAMMA Investing LLC boosted its position in shares of Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares during the period. First Dallas Securities Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter worth approximately $73,000. Finally, Diversified Trust Co acquired a new stake in Ironwood Pharmaceuticals during the 3rd quarter worth approximately $52,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.